Heart

Heartseed is a clinical-stage biotechnology company specializing in the development of induced pluripotent stem cell (iPSC)-derived cardiac regenerative medicine. The company's lead pipeline candidate, HS-001, consists of purified, high-quality ventricular cardiomyocyte spheroids designed to engraft into the failing heart and restore cardiac function. By utilizing a proprietary purification process and a specialized delivery device, Heartseed aims to overcome the limitations of traditional cell therapies, such as low retention and engraftment rates. The company is currently conducting clinical trials for heart failure with reduced ejection fraction (HFrEF) and has established a significant global partnership with Novo Nordisk to advance its lead program.